Skip to main content

RXi Acquires Ownership of Previously Licensed RNAi Delivery Technology

Premium

RXi Pharmaceuticals said last week that it has acquired direct ownership of a self-delivering RNAi technology it had previously licensed from Advirna.

In July, RXi announced that it had acquired an exclusive licensed to the technology, which was developed by a Boulder, Colo.-based biotech firm co-founded by the company's CSO (see RNAi News, 7/30/2009).

"By combining this newly acquired technology into RXi's own portfolio and gaining full control of the patent prosecution, we enhance the potential of obtaining broader claims that would further strengthen RXi's intellectual property position," RXi President and CEO Tod Woolf said in a statement.

Terms of the deal with Advirna were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.